Management Team

 

The Isogenica management team have collective expertise in the discovery and development of next generation antibody therapeutics, combining backgrounds from companies such as Ablynx, Cambridge Antibody Technology and Bicycle Therapeutics.

 

 

Carolyn Rand

Chief Executive Officer

Emma joined Isogenica as Chief Executive Officer in September 2018. She is passionate about technologies that can accelerate drug discovery and development, and experienced in leading highly innovative, scientific companies from start-up through multiple product launches, to rapidly growing sustainable businesses.

Director of Business Development

 

David joined Isogenica in 2019. He brings in over twenty years of experience in Life Sciences discovery and has held a number of senior positions in R&D, GMP manufacturing, intellectual property and licensing.

Chief Scientific Officer

 

Guy joined Isogenica in 2016. He brings in over a decade of experience in antibody fragment discovery and early development, as well as antibody discovery technology development.

Director of Antibody Technology Development

Edward joined Isogenica in 2016 following a decade in biopharma at CAT/MedImmune and latterly at Bicycle Therapeutics.

Associate Director of Alliance Management

Claudia joined Isogenica in 2009 and has contributed significantly to LlamdA™ library build and managing biopharma collaborations.